A Phase 1, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Vonapanitase Administered Following Angioplasty of a Distal Popliteal, Tibial or Peroneal Artery in Patients With Peripheral Artery Disease

Trial Profile

A Phase 1, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study of Vonapanitase Administered Following Angioplasty of a Distal Popliteal, Tibial or Peroneal Artery in Patients With Peripheral Artery Disease

Recruiting
Phase of Trial: Phase I

Latest Information Update: 10 May 2017

At a glance

  • Drugs Vonapanitase (Primary)
  • Indications Peripheral arterial disorders
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Proteon Therapeutics
  • Most Recent Events

    • 10 May 2017 According to a Proteon Therapeutics media release, the company is on track to enroll 24 patients in this trial by the end of 2017.
    • 10 Nov 2016 According to a Proteon Therapeutics media release, first patient has been dosed in this trial.
    • 16 Mar 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top